A randomized trial to compare the efficacy and safety of antiemetic treatment with ondansetron and ondansetron zydis in patients with breast cancer treated with high-dose epirubicin
Date
2007Author
Pectasides, DimitriosDafni, U.
Aravantinos, Gerasimos
Timotheadou, E.
Skarlos, Dimosthenis V.
Pavlidis, Nicholas
Gaglia, A.
Kalofonos, H. P.
Fountzilas, George
Source
Anticancer ResearchVolume
27Issue
6 CPages
4411-4417Google Scholar check
Keyword(s):
Metadata
Show full item recordAbstract
Objective: The objective of this study was to compare the efficacy of a disintegrating tablet of ondansetron (ODT) and the conventional tablet formulation of ondansetron (OT) in controlling nausea and vomiting in breast cancer patients. Patients and Methods: A total of 134 breast cancer patients receiving high-dose epirubicin participated in a randomized trial comparing the antiemetic efficacy and safety of an 8 mg OT given twice daily to an 8 mg orally ODT given twice daily, both for 3 days. Results: OT was significantly better in the complete control of emesis (72% versus 52%, p=0.020) and marginally better in the complete control of nausea (66% versus 48%, p=0.054) induced by high-dose epirubicin over days 1-3 compared to ODT. However, no differences were found in major control of emesis (0 to 2 emetic episodes, 76% versus 70%, p=0.28) over days 1-3. Conclusion: OT was significantly better in the complete control of emesis and marginally better in the complete control of nausea, but not in the major control of emesis and nausea induced by high-dose epirubicin compared to ODT. ODT may be an effective alternative to OT, particularly in patients who have difficulties in swallowing a conventional tablet.
Collections
Cite as
Related items
Showing items related by title, author, creator and subject.
-
Article
Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: A randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG)
Skarlos, Dimosthenis V.; Samantas, E.; Briassoulis, E. Ch; Panoussaki, E.; Pavlidis, Nicholas; Kalofonos, H. P.; Kardamakis, D.; Tsiakopoulos, E.; Kosmidis, Paraskevas A.; Tsavdaridis, D.; Tzitzikas, J.; Tsekeris, P.; Kouvatseas, G.; Zamboglou, N.; Fountzilas, George (2001)Background: Concurrent platinum-etoposide chemotherapy given in combination with hyperfractionated thoracic radiation therapy (HTRT) in limited disease (LD) small cell lung cancer (SCLC) is associated with a high response ...
-
Article
Design considerations for nanotherapeutics in oncology
Stylianopoulos, T.; Jain, R. K. (2015)Nanotherapeutics have improved the quality of life of cancer patients, primarily by reducing the adverse effects of chemotherapeutic agents, but improvements in overall survival are modest. This is in large part due to the ...
-
Article
Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis
Golfinopoulos, Vassilis; Salanti, G.; Pavlidis, Nicholas; Ioannidis, J. P. A. (2007)Background: Many randomised trials have compared different systemic treatment regimens in patients with advanced colorectal cancer. While survival advances have apparently been achieved, the magnitude of these incremental ...